← Leaderboards
Patrick Thompson
Baylor College Of Medicine
$152,787
Attributed
$152,787
Total exposure
20
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $64.7K · FY2009–11$100K$75K$50K$25K$0
'09
'10
'11
Funding mix
By agency
NIH$152,787 · 20
By mechanism
M01$152,787 · 20
Top collaborators
No co-investigators on record.
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Susan M Blaney$10,519,074
Others in their field
Top investigators on “Funding”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,479,940,681
- Leonard Freedman · Leidos Biomedical Research, Inc.$968,195,877
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Jeffrey P Krischer · University Of South Florida$358,470,093
Research focus
FundingResourcesUnited States National Institutes Of HealthSourceGrantChildRefractoryDoseToxic EffectSolid NeoplasmDrug KineticsClinical ResearchClinical TrialsTumorMalignant NeoplasmsPhase I Clinical TrialsComputer Retrieval Of Information On Scientific Projects DatabaseResearch PersonnelInstitutionPhase 1 StudyMaximum Tolerated DoseResearch InfrastructureInhibitor/AntagonistSchedule
Grant awards (20)
H-26071 ADVL0916 - A PHASE I STUDY OF VORINOSTAT AND BORTEZOMIB IN CHILDREN WITH$14,247
M01 · FY2011 · RR · contact PI
H-25893 ADVL0912, A PHASE 1/2 STUDY OF PF-02341066, AN ORAL SMALL MOLECULE$12,665
M01 · FY2011 · RR · contact PI
CLINICAL TRIAL: H-25421: ADVL0815: A PHASE I STUDY OF PAZOPANIB AS A SINGLE AGE$9,498
M01 · FY2011 · RR · contact PI
CLINICAL TRIAL: ADVL0813 A PHASE I STUDY OF IMC-A12 (ANTI-INSULIN-LIKE GROWTH F$6,332
M01 · FY2011 · RR · contact PI
ADVL06B1 A PHARMACOKINETIC-PHARMACODYNAMIC PHARMACOGENETIC STUDY OF ACTINOMYCIN-$5,323
M01 · FY2011 · RR · contact PI
ADVL0911 A PHASE 1 DOSE ESCALATION STUDY OF SENECA$4,749
M01 · FY2011 · RR · contact PI
ADVL0919: A PHASE 1 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMM$4,749
M01 · FY2011 · RR · contact PI
CLINICAL TRIAL: A PHASE I STUDY OF VORINOSTAT AND TEMOZOLOMIDE$3,562
M01 · FY2011 · RR · contact PI
CLINICAL TRIAL: A PHASE 1 STUDY OF TEMSIROLIMUS IN COMBINATION WITH IRINOTECAN$3,562
M01 · FY2011 · RR · contact PI
ADVL06B1 A PHARMACOKINETIC-PHARMACODYNAMIC PHARMACOGENETIC STUDY OF ACTINOMYCIN-$17,549
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: H-23957 ADVL0812 A PHASE I STUDY OF MLN8237, AN ORAL SELECTIVE S$13,734
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: H-22658 - ADVL0712 - A PHASE I STUDY OF IMC-A12 (ANTI-IGF-I$9,156
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: ADVL0714, A PHASE I STUDY OF VEGF TRAP (NSC #724770, IND#$2,670
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: A PHASE I STUDY OF THE RAF KINASE AND RECEPTOR TYROSINE KINASE I$1,145
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: H-22658 - ADVL0712 - A PHASE I STUDY OF IMC-A12 ANTI-IGF-I$18,368
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: A PHASE I STUDY OF THE RAF KINASE AND RECEPTOR TYROSINE KINASE I$11,258
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: ADVL0714, A PHASE I STUDY OF VEGF TRAP$5,925
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: ADVL0414, A PHASE I STUDY OF TEMOZOLOMIDE, ORAL IRINOTECAN, AND$3,851
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: A PHASE I STUDY OF SUNITINIB (SU11248), AN ORAL MULTI-TARGETED T$2,962
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: ADVL0419, A PHASE I STUDY OF VALPROIC ACID IN CHILDREN WITH RECU$1,482
M01 · FY2009 · RR · contact PI